Effects of DPP4 Inhibitors as Neuroprotective Drug on Cognitive Impairment in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis and Systematic Review
Wirkungen von DPP4-Inhibitoren als neuroprotektive Medikamente auf kognitive Beeinträchtigung bei Patient:innen mit Typ-2-Diabetes mellitus: Metaanalyse und systematische Übersichtsarbeit
International Journal of Endocrinology · 13.02.2024 · 2024 · 1-10
DOI: 10.1155/2024/9294113 ↗Auf einen Blick
Die Metaanalyse zeigte bei Patient:innen mit Typ-2-Diabetes eine geringere kognitive Beeinträchtigung unter DPP4-Inhibitoren. Auch Nüchternblutzucker, 2-Stunden-Postprandialblutzucker und HbA1c waren reduziert.
Fragestellung
Besteht bei Patient:innen mit Typ-2-Diabetes mellitus ein Zusammenhang zwischen DPP4-Inhibitoren und kognitiver Beeinträchtigung?
Methode
Systematische Suche in PubMed, CNKI und der Cochrane Library bis 2022; Metaanalyse der eingeschlossenen Studien.
Ergebnisse
10 Studien mit 5.583 Teilnehmenden. Kognitive Beeinträchtigung: SMD 0,99 (95 %-KI 0,59–1,38). FPG: SMD 0,52 (95 %-KI −0,68 bis −0,37). 2hPPG: SMD 0,82 (95 %-KI −1,2 bis −0,43). HbA1c: SMD 0,34 (95 %-KI −0,48 bis −0,21).
Schlussfolgerung der Autor:innen
DPP4-Inhibitoren verbesserten laut Autor:innen die kognitive Beeinträchtigung bei Menschen mit Typ-2-Diabetes und senkten FPG, 2hPPG und HbA1c.
Kernaussagen
- 10 Studien mit 5.583 Teilnehmenden
- Kognitive Beeinträchtigung unter DPP4-Inhibitoren geringer
- FPG, 2hPPG und HbA1c ebenfalls reduziert
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Endocrinology, erschienen am 13.02.2024. Verfasst von Yuting Yuan und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning, Hubei, China. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Development and Utilization of Experimental Animal Resources in Hubei Province, Natural Science Foundation of Hubei Province.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Purpose
Type 2 diabetes mellitus is considered as one of the risk factors for cognitive impairment. DPP4 inhibitors are effective drugs for the treatment of type 2 diabetes mellitus. However, the relationship between DPP4 inhibitors and cognitive dysfunction remains unclear. Therefore, we used a meta-analysis to determine the association between DPP4 inhibitors and cognitive impairment in type 2 diabetes mellitus.
Methods
We systematically searched PubMed, CNKI, and the Cochrane Library at the time of establishment, 2022, and then made inclusion criteria and screened strategies to identify studies with more precise correlations.
Results
We included 10 studies with 5,583 participants. The data showed that DPP4 inhibitors significantly reduced the incidence rate of cognitive impairment in type 2 diabetes mellitus (SMD: 0.99; 95% CI [0.59, 1.38]). Furthermore, there was a linear correlation found between cognitive impairment in type 2 diabetes mellitus and fasting blood glucose, 2-hour postprandial blood glucose, and glycosylated hemoglobin. DPP4 inhibitors decreased fasting blood glucose (FPG) (SMD: 0.52; 95% CI [−0.68, −0.37]), blood glucose (2hPPG) at 2 hours after the meal (SMD: 0.82; 95% CI, [−1.2, −0.43]), and HbA1c (SMD: 0.34; 95% CI [−0.48, −0.21]). All data were statistically significant ( P < 0.0001 ). Furthermore, we conducted subgroup analyses of the following measures at various treatment durations and ages: cognitive scores, fasting blood glucose, glycosylated hemoglobin, and two-hour postprandial blood glucose.
Conclusion
DPP4 inhibitors significantly improved type 2 diabetic mellitus individuals’ cognitive impairment and reduced fasting blood glucose, 2-hour postprandial blood glucose, and glycosylated hemoglobin. Subgroup analysis showed that people aged 60 to 70 years had better treatment effects at 0–180 days. This trial is registered with CRD42023399473.
Autor:innen und Institutionen
- School of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning, Hubei, China.
- Hubei Key Laboratory of Diabetes and Angiopathy, Medicine Research Institute, Xianning Medical College, Hubei University of Science and Technology, Xianning, Hubei, China.
ORCID-Profile: Yuting Yuan, Chao Liu, Qingjie Chen
Förderung
- National Natural Science Foundation of China
- Development and Utilization of Experimental Animal Resources in Hubei Province
- Natural Science Foundation of Hubei Province
- Xianning City Science and Technology Plan Project
- Hubei University of Science and Technology
Zitieren
APA
Yuan, Y., Zhang, Y., Lei, M., Guo, X., Yang, X., Ouyang, C., Liu, C., & Chen, Q. (2024). Effects of DPP4 Inhibitors as Neuroprotective Drug on Cognitive Impairment in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis and Systematic Review. International Journal of Endocrinology, 2024, 1-10. https://doi.org/10.1155/2024/9294113
Vancouver
Yuan Y, Zhang Y, Lei M, Guo X, Yang X, Ouyang C, et al. Effects of DPP4 Inhibitors as Neuroprotective Drug on Cognitive Impairment in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis and Systematic Review. International Journal of Endocrinology. 2024;2024:1-10. doi:10.1155/2024/9294113
BibTeX
@article{Yuan2024,
author = {Yuan, Yuting and Zhang, Yue and Lei, Min and Guo, Xiying and Yang, Xiaosong and Ouyang, Changhan and Liu, Chao and Chen, Qingjie},
title = {Effects of DPP4 Inhibitors as Neuroprotective Drug on Cognitive Impairment in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis and Systematic Review},
journal = {International Journal of Endocrinology},
year = {2024},
volume = {2024},
pages = {1--10},
doi = {10.1155/2024/9294113}
}
EUVIMED